Brought to you by 
Halozyme grants Pfizer license to Enhanze platform for biologics development
28 Aug 2017
Executive Summary
Drug delivery firm Halozyme Therapeutics Inc. has licensed Pfizer Inc. worldwide rights to its Enhanze technology, which the Big Pharma will initially use to develop a therapeutic against two targets for primary care and specialty care indications.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Halozyme grants Pfizer license to Enhanze platform for biologics development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice